Alembic Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.1K Cr

Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions. - U.S. Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.

From Alembic Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹822

Market Cap

₹16.1K Cr

P/E Ratio

21.6

How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 3

View Pharmaceuticals & Biotechnology leaderboard →

Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹202 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 3

→Alembic Pharmaceuticals targets low double-digit consolidated revenue growth in FY '27, driven by internal performance improvements amid stable external market conditions.
→U.S. business expected to grow 10-15% in INR terms (approximately 7-8% in constant currency).
→Rest of World (ex-U.S.) markets projected to grow 15%+ driven by new product launches and expanding footprints.
→API business anticipated to grow around 10%, supported by volume increases.
→India business aims to improve growth momentum, targeting growth closer to the overall market.
→New product launches, especially Day 1 and First-to-File opportunities, along with contract manufacturing, will support volume growth.
→The U.S. branded business is in a launch phase, expected to scale and contribute meaningfully in the next few quarters.
→R&D investments continue to underpin growth through innovation and complex product development.

📈 Profitability & Margins

Rank 3

→Alembic expects low double-digit consolidated top-line growth in FY '27 driven by international generics, API, and India businesses.
→U.S. business projected to grow 10-15% in INR terms; ex-U.S. markets expected to grow 15+%.
→EBITDA margins expected to improve: core business margins to offset drag from the new U.S. branded business (Pivya), which may impact margins by 100-150 basis points initially.
→R&D spends will increase to INR 750-800 crores with focus on complex products and peptide pipeline, measured by IRR, aiming for improved medium-term returns.
→The company targets a return to ~20% EBITDA margins over a 2-3 year period, with FY '27 anticipated as a year where margin improvement begins.
→Earnings growth driven by improved operating leverage, cost savings, and selective investments in differentiated portfolios.
→Profit after tax grew 16% in FY '26, with expectations of continued profitability improvement aligned with growth and margin expansion.

See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex.
→The branded business, including U.S. specialty branded operations like Pivya, does not require significant capex; investments are primarily in in-licensing products.
→For FY '27, capital expenditure is expected in the range of INR 300-350 crores, focused on capacity expansion, debottlenecking, and replacement capex.
→There will be continued, though measured, R&D investments (~INR 750-800 crores) to support complex products and expansion of the branded business.
→New product launches, increased utilization of F2 and F3 facilities, and contract manufacturing deals contribute to strategic growth without significant new capex.
→Strategic focus remains on quality portfolio additions, operating leverage, working capital management, and calibrated brand business expansion.

💰 Fundraising & Capital Structure

No information

→There is no specific mention of any current or future new fundraising through debt or equity in the transcript.
→Gross debt stood at INR 1,361 crores, broadly in line with December levels, indicating no significant new borrowing.
→Capital expenditure for FY '27 is expected to be INR 300-350 crores, directed towards capacity, debottlenecking, and replacement capex, with no indication of additional fundraising to support this.
→The company is focusing on capital-efficient execution and working capital management.
→Investments are mainly focused on R&D (INR 750-800 crores) and in-licensing for branded business, funded from existing resources.
→No guidance or mention of plans for raising funds through equity or additional debt was provided during the call.

See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information

The transcript from Alembic Pharmaceuticals Limited's Q4 FY '26 Earnings Conference Call does not explicitly mention the current or expected order book or pending orders. However, the following related points can be inferred: - Alembic expects product launches in the U.S. and ex-U.S. markets to be phased through FY '27, indicating an active pipeline for launches. - The company mentioned having a portfolio of 5-6 peptide filings, with two already filed and others ongoing, suggesting pending developmental projects. - Contract manufacturing deals for F2 and F3 facilities are already in progress, contributing to revenue in FY '27, implying active orders or partnerships. - Alembic is pursuing in-licensing on the branded side to build the portfolio, indicating ongoing and future product additions. - Overall business growth guidance points to a low double-digit consolidated revenue growth for FY '27, reflecting expected increasing order flow and market activity. No specific order book values or exact pending order quantities were disclosed.

Key Metrics

1 of 5 growth signals positive in the Q4 FY26 call.

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alembic Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

What Alembic Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
SAIPARENT (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alembic Pharmaceuticals Ltd Q4 FY26 results?

What is Alembic Pharmaceuticals Ltd share price analysis?

Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alembic Pharmaceuticals Ltd planning capital expenditure?

Alembic Pharmaceuticals is broadly done with all major capex, including peptide-related investments, which were part of ongoing API facility upgrades rather than dedicated peptide capex. - The branded business, including U.S.

Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit

📊 Revenue & Sales Performance

🏗️ Capital Expenditure Plans

📋 Order Book & Pipeline

Key Metrics

Continue your research

What Alembic Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Frequently Asked Questions